The ATO assay demonstrated that the patient’s T cell precursors were capable of fully differentiating ex vivo into single positive CD4 and CD8 T cells suggesting that CTTI may provide definitive treatment for her T cell lymphopenia. The gene discussed is CD4; the disease is lymphopenia.